Last reviewed · How we verify
TEVIMBRA (islelizumab-jsgr)
TEVIMBRA (generic name: islelizumab-jsgr) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by BEIGENE. It is currently FDA-approved.
At a glance
| Generic name | islelizumab-jsgr |
|---|---|
| Sponsor | BEIGENE |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Decreased neutrophil count
- Decreased sodium
- Increased glucose
- Anemia
- Fatigue
- Decreased appetite
- Increased AST
- Decreased potassium
- Increased serum creatinine
- Decreased calcium
- Increased ALT
- Diarrhea
Serious adverse events
- Fatal adverse reactions
- Pneumonia
- Dysphagia
- Diarrhea
- Fatigue
- Esophageal stenosis
- Pneumonitis
Key clinical trials
- A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab in P (Phase 1)
- A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients (Phase 3)
- Short-course PD-1 Blockade As Adjuvant Treatment for High-risk Stage-II DMMR/MSI-H Colorectal Cancer (Phase 3)
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors (Phase 1)
- A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217 (Phase 2)
- - IKF/AIO-QUINTIS - A Randomized Phase II Trial Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer W (Phase 2)
- A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combination (Phase 1)
- A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection As a Single and Combination with Tislelizumab in Subjects with Advan (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEVIMBRA CI brief — competitive landscape report
- TEVIMBRA updates RSS · CI watch RSS
- BEIGENE portfolio CI
Frequently asked questions about TEVIMBRA
What is TEVIMBRA?
TEVIMBRA (islelizumab-jsgr) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by BEIGENE.
Who makes TEVIMBRA?
TEVIMBRA is developed and marketed by BEIGENE (see full BEIGENE pipeline at /company/beigene).
What is the generic name of TEVIMBRA?
islelizumab-jsgr is the generic (nonproprietary) name of TEVIMBRA.
What drug class is TEVIMBRA in?
TEVIMBRA belongs to the Programmed Death Receptor-1 Blocking Antibody [EPC] class. See all Programmed Death Receptor-1 Blocking Antibody [EPC] drugs at /class/programmed-death-receptor-1-blocking-antibody-epc.
What development phase is TEVIMBRA in?
TEVIMBRA is FDA-approved (marketed).
What are the side effects of TEVIMBRA?
Common side effects of TEVIMBRA include Decreased neutrophil count, Decreased sodium, Increased glucose, Anemia, Fatigue, Decreased appetite. Serious adverse events: Fatal adverse reactions, Pneumonia, Dysphagia, Diarrhea.
Related
- Drug class: All Programmed Death Receptor-1 Blocking Antibody [EPC] drugs
- Manufacturer: BEIGENE — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing